This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs
by Kinjel Shah
J&J tops third-quarter earnings and sales estimates. FDA approves new drugs of Pfizer, Roche and AbbVie.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold
by Zacks Equity Research
NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the combo shot reported nerve damage.
Moderna Stock Falls 20% in a Month: Time to Sell or Hold?
by Sundeep Ganoria
Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.
Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 9.01% and 1.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Pfizer (PFE) stood at $29.08, denoting a -0.27% change from the preceding trading day.
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
by Zacks Equity Research
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be administered via a pre-filled, auto-injector pen.
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
by Zacks Equity Research
GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted population. A potential approval should boost GILD???s HIV portfolio.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy
by Zacks Equity Research
New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV seasons in adults aged 60 years and above.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
by Zacks Equity Research
While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Pfizer (PFE) stood at $29.18, denoting a -0.07% change from the preceding trading day.
Pfizer Receives $1 Billion From Starboard Value, Stock Rises
by Zacks Equity Research
PFE obtains $1 billion from activist investor Starboard Value. Stock gains on hopes of a plausible turnaround of the struggling pharma giant.
Company News for Oct 8, 2024
by Zacks Equity Research
Companies in The News Are: PFE,WYNN,GOOGl,APD
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
by Zacks Equity Research
Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.
5 Large Drug Stocks to Watch From a Thriving Industry
by Kinjel Shah
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Pfizer (PFE) stood at $28.61, denoting a -0.21% change from the preceding trading day.
Zacks Investment Ideas feature highlights: Coca-Cola, Pfizer and Altria
by Zacks Equity Research
Coca-Cola, Pfizer and Altria have been highlighted in this Investment Ideas article.
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
by Zacks Equity Research
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
3 Consistent Dividend Stocks for Passive Income: KO, PFE, MO
by Derek Lewis
Everybody loves dividends, essentially investors' form of payday. And these companies have been paying shareholders consistently for years.
Zacks.com featured highlights include GIII Apparel Group, Sonoco Products, Hamilton Insurance Group, Pampa Energia S.A. and Pfizer
by Zacks Equity Research
GIII Apparel Group, Sonoco Products, Hamilton Insurance Group, Pampa Energia S.A. and Pfizer are part of the Zacks Screen of the Week article.
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
by Zacks Equity Research
Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.